MONITOR ( DrugBank: MONITOR )

4 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	1
11	Myasthenia gravis	1
81	Congenital adrenal hyperplasia	1
129	Acute encephalopathy with biphasic seizures and late reduced diffusion	1

2. Amyotrophic lateral sclerosis

Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000002276	2009/08/01	01/08/2009	Developmental research of communication devices based on the brain machine interface using electroencephalograms	Developmental research of communication devices based on the brain machine interface using electroencephalograms - Communication devices using EEG-based BMI	amyotrophic lateral sclerosis	Let the patients use the communication devices to select characters on a computer monitor as they intend by recording EEG.	Osaka University	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	10	Not applicable	Japan

11. Myasthenia gravis

Clinical trials : 332 / Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR-OCC-14004533	2014-04-30	2014-04-16	The superior anesthetic management scheme during perioperative period for myasthenia gravis patients	The superior anesthetic management scheme during perioperative period for myasthenia gravis patients	myasthenia gravis	volunteer:muscle relaxant monitor;MG group:muscle relaxant monitor;	Yijishan Hospital, Wannan Medical College, Wuhu 241001, China	NULL	Completed	10	66	Both	volunteer:30;MG group:30;		China

81. Congenital adrenal hyperplasia

Clinical trials : 87 / Drugs : 87 - (DrugBank : 23) / Drug target genes : 12 - Drug target pathways : 68

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2031210491	04/01/2022	17/12/2021	Double-blind comparison of Chronocort versus standard hydrocortisonereplacement therapy in participants aged 16 years and over with congenital adrenalhyperplasia	A randomized, Double-Blind, Active-Controlled, Phase 3 Study ofChronocort Compared with Immediate-Release Hydrocortisone Replacement Therapy inParticipants Aged 16 Years and Over with Congenital Adrenal Hyperplasia	Congenital adrenal hyperplasia (CAH)	Participants randomized to Chronocort will receive 10 mg Chronocort in the morning on waking (typically between 06:00 and 08:00), placebo in the afternoon (between 15:00 and 17:00) and 20 mg Chronocort at night just prior to going to bed (typically between 22:00 and midnight). A maximum of 3 dose reductions will be allowed, resulting in a minimum final dose of 15 mg a day. Participants randomized to immediate-release hydrocortisone (IRHC) will receive 20 mg IRHC in the morning on waking (typically between 06:00 and 08:00), 10 mg IRHC in the afternoon (between 15:00 and 17:00) and placebo at night just prior to going to bed (typically between 22:00 and midnight). A maximum of 3 dose reductions will be allowed, resulting in a minimum final dose of 15 mg a day. The dose for both groups will be adjusted by an Independent blinded physician based on the androgen levels and adrenal function at Weeks 4, 10, and 16. At Week 16 the dose will be fixed and should remain unchanged. The blinded titrator can complete a dose increase at week 32 of 5 mg based on androgen results and adrenal function. Additionally, if a participant shows persistent signs of under replacement the Investigator can request 1 dose reversion of 5 mg, this will be discussed and agreed by the medical monitor.	Fujii Katsuya	NULL	Recruiting	>= 16age old	Not applicable	Both	15	Phase 2	US;France;Turkey;Japan

129. Acute encephalopathy with biphasic seizures and late reduced diffusion

Clinical trial : 1 / Drug : 1 - (DrugBank : 1) / Drug target gene : 0 - Drug target pathway : 0

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000041484	2020/04/10	21/08/2020	The Safety and synergetic/additive neuroprotective effect of remote ischaemic postconditioning to therapeutic hypothermia in pediatric patients with acute encephalopathy with biphasic seizures and late reduced diffusion	Synergetic/additive neuroprotection of remote ischaemic postconditioning to therapeutic hypothermia in pediatric patients with acute encephalopathy with biphasic seizures and late reduced diffusion - Synergetic/additive neuroprotection of remote ischaemic postconditioning to therapeutic hypothermia in pediatric patients with acute encephalopathy with biphasic seizures and late reduced diffusion	Acute encephalopathy with biphasic seizures and late reduced diffusion or suspected	RIPoC (4 cycles of inflation 5 mins and deflation 5 mins) applied on a lower extremity using a blood pressure monitor cuff with 200 mmHg.	Paediatrics, St Mary's Hospital	NULL	Recruiting	1months-old	192months-old	Male and Female	14	Phase 2	Japan